Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis

Talal Hilal, Zhen Wang, Diana Almader-Douglas, Allison Rosenthal, Craig B. Reeder, Tania Jain

Research output: Contribution to journalArticle

Abstract

Mantle cell lymphoma is characterized by relapse and progressive disease, despite initial response to chemoimmunotherapy. We conducted a systematic review and meta-analysis to determine the efficacy of rituximab maintenance (RM) therapy in patients with mantle cell lymphoma. We searched PubMed, Embase and Cochrane Central Register of Controlled Trials from database inception through November 1, 2017. Only full-text articles were included. Prespecified data elements were extracted from each trial. Outcomes of interest included progression-free survival (PFS) and overall survival (OS). The overall effect was pooled using the Der Simonian-Laird random effects model. Three randomized controlled trials and four observational studies met our inclusion criteria and were identified in the analyses. Six studies compared RM therapy to observation, and one compared RM therapy to interferon alfa. Meta-analysis evaluating outcomes of patients treated after ASCT revealed that RM improved for both PFS (HR = 0.33, 95% CI = 0.23-0.49) and OS (HR of death = 0.35, 95% CI = 0.17-0.69). A second meta-analysis of studies evaluating outcomes of patients who are ASCT-ineligible treated with anthracycline-based induction therapy revealed that RM improved PFS (HR = 0.38, 95% CI = 0.25-0.58). There is a paucity of data on the role of RM in ASCT-ineligible patients and those with relapsed disease. Overall, RM therapy appears to improve PFS and OS in previously untreated patients with mantle cell lymphoma who undergo induction chemoimmunotherapy followed by ASCT.

Original languageEnglish (US)
Pages (from-to)1220-1226
Number of pages7
JournalAmerican Journal of Hematology
Volume93
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Mantle-Cell Lymphoma
Meta-Analysis
Disease-Free Survival
Therapeutics
Survival
Anthracyclines
Rituximab
PubMed
Interferon-alpha
Observational Studies
Randomized Controlled Trials
Observation
Outcome Assessment (Health Care)
Databases
Recurrence

ASJC Scopus subject areas

  • Hematology

Cite this

Rituximab maintenance therapy for mantle cell lymphoma : A systematic review and meta-analysis. / Hilal, Talal; Wang, Zhen; Almader-Douglas, Diana; Rosenthal, Allison; Reeder, Craig B.; Jain, Tania.

In: American Journal of Hematology, Vol. 93, No. 10, 01.10.2018, p. 1220-1226.

Research output: Contribution to journalArticle

Hilal, Talal ; Wang, Zhen ; Almader-Douglas, Diana ; Rosenthal, Allison ; Reeder, Craig B. ; Jain, Tania. / Rituximab maintenance therapy for mantle cell lymphoma : A systematic review and meta-analysis. In: American Journal of Hematology. 2018 ; Vol. 93, No. 10. pp. 1220-1226.
@article{22de1f43688340669db31b3ded2d1566,
title = "Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis",
abstract = "Mantle cell lymphoma is characterized by relapse and progressive disease, despite initial response to chemoimmunotherapy. We conducted a systematic review and meta-analysis to determine the efficacy of rituximab maintenance (RM) therapy in patients with mantle cell lymphoma. We searched PubMed, Embase and Cochrane Central Register of Controlled Trials from database inception through November 1, 2017. Only full-text articles were included. Prespecified data elements were extracted from each trial. Outcomes of interest included progression-free survival (PFS) and overall survival (OS). The overall effect was pooled using the Der Simonian-Laird random effects model. Three randomized controlled trials and four observational studies met our inclusion criteria and were identified in the analyses. Six studies compared RM therapy to observation, and one compared RM therapy to interferon alfa. Meta-analysis evaluating outcomes of patients treated after ASCT revealed that RM improved for both PFS (HR = 0.33, 95{\%} CI = 0.23-0.49) and OS (HR of death = 0.35, 95{\%} CI = 0.17-0.69). A second meta-analysis of studies evaluating outcomes of patients who are ASCT-ineligible treated with anthracycline-based induction therapy revealed that RM improved PFS (HR = 0.38, 95{\%} CI = 0.25-0.58). There is a paucity of data on the role of RM in ASCT-ineligible patients and those with relapsed disease. Overall, RM therapy appears to improve PFS and OS in previously untreated patients with mantle cell lymphoma who undergo induction chemoimmunotherapy followed by ASCT.",
author = "Talal Hilal and Zhen Wang and Diana Almader-Douglas and Allison Rosenthal and Reeder, {Craig B.} and Tania Jain",
year = "2018",
month = "10",
day = "1",
doi = "10.1002/ajh.25226",
language = "English (US)",
volume = "93",
pages = "1220--1226",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Rituximab maintenance therapy for mantle cell lymphoma

T2 - A systematic review and meta-analysis

AU - Hilal, Talal

AU - Wang, Zhen

AU - Almader-Douglas, Diana

AU - Rosenthal, Allison

AU - Reeder, Craig B.

AU - Jain, Tania

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Mantle cell lymphoma is characterized by relapse and progressive disease, despite initial response to chemoimmunotherapy. We conducted a systematic review and meta-analysis to determine the efficacy of rituximab maintenance (RM) therapy in patients with mantle cell lymphoma. We searched PubMed, Embase and Cochrane Central Register of Controlled Trials from database inception through November 1, 2017. Only full-text articles were included. Prespecified data elements were extracted from each trial. Outcomes of interest included progression-free survival (PFS) and overall survival (OS). The overall effect was pooled using the Der Simonian-Laird random effects model. Three randomized controlled trials and four observational studies met our inclusion criteria and were identified in the analyses. Six studies compared RM therapy to observation, and one compared RM therapy to interferon alfa. Meta-analysis evaluating outcomes of patients treated after ASCT revealed that RM improved for both PFS (HR = 0.33, 95% CI = 0.23-0.49) and OS (HR of death = 0.35, 95% CI = 0.17-0.69). A second meta-analysis of studies evaluating outcomes of patients who are ASCT-ineligible treated with anthracycline-based induction therapy revealed that RM improved PFS (HR = 0.38, 95% CI = 0.25-0.58). There is a paucity of data on the role of RM in ASCT-ineligible patients and those with relapsed disease. Overall, RM therapy appears to improve PFS and OS in previously untreated patients with mantle cell lymphoma who undergo induction chemoimmunotherapy followed by ASCT.

AB - Mantle cell lymphoma is characterized by relapse and progressive disease, despite initial response to chemoimmunotherapy. We conducted a systematic review and meta-analysis to determine the efficacy of rituximab maintenance (RM) therapy in patients with mantle cell lymphoma. We searched PubMed, Embase and Cochrane Central Register of Controlled Trials from database inception through November 1, 2017. Only full-text articles were included. Prespecified data elements were extracted from each trial. Outcomes of interest included progression-free survival (PFS) and overall survival (OS). The overall effect was pooled using the Der Simonian-Laird random effects model. Three randomized controlled trials and four observational studies met our inclusion criteria and were identified in the analyses. Six studies compared RM therapy to observation, and one compared RM therapy to interferon alfa. Meta-analysis evaluating outcomes of patients treated after ASCT revealed that RM improved for both PFS (HR = 0.33, 95% CI = 0.23-0.49) and OS (HR of death = 0.35, 95% CI = 0.17-0.69). A second meta-analysis of studies evaluating outcomes of patients who are ASCT-ineligible treated with anthracycline-based induction therapy revealed that RM improved PFS (HR = 0.38, 95% CI = 0.25-0.58). There is a paucity of data on the role of RM in ASCT-ineligible patients and those with relapsed disease. Overall, RM therapy appears to improve PFS and OS in previously untreated patients with mantle cell lymphoma who undergo induction chemoimmunotherapy followed by ASCT.

UR - http://www.scopus.com/inward/record.url?scp=85052917165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052917165&partnerID=8YFLogxK

U2 - 10.1002/ajh.25226

DO - 10.1002/ajh.25226

M3 - Article

C2 - 30033656

AN - SCOPUS:85052917165

VL - 93

SP - 1220

EP - 1226

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 10

ER -